Foghorn Therapeutics Inc. at Cowen Oncology Innovation Summit: Insights for ASCO & EHA (Virtual) Transcript
Okay. Well, good morning, everybody. We're just going to wait a few seconds to let everybody into the session, and we'll get started in a minute.
Well, good morning, everybody, and thank you for joining us for the Third Annual Oncology Innovation Summit. I'm Yaron Werber, one of the biotech analysts here at Cowen. And it's a great pleasure to moderate the next fireside chat or webinar with Adrian Gottschalk, President and CEO of Foghorn Therapeutics. Adrian, always good to see you. Thanks for joining us.
Yeah, great to see you, too. Thanks for having me today. Pleasure to be chatting.
Questions & Answers
So lots to talk about with respect to your first program, FHD-286. Let's talk about -- you're enrolling patients currently or you have been enrolling patients in the relapsed/refractory AML and uveal melanoma study. Are there any
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
